ArticleFrontiers in immunology2026

A multimodal biological margin risk index predicts recurrence after neoadjuvant immunochemotherapy in head and neck squamous cell carcinoma.

Ning Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.